Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

State Street SPDR S&P Pharmaceuticals ETF (NY:XPH)

63.62 +0.72 (+1.14%)
Delayed Quote Updated: 1:45 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Pharmaceuticals ETF

< Previous 1 2 3 Next >
News headline image
Which Healthcare ETF Is the Better Buy: State Street’s Pharma XPH or Simplify’s Mission-Driven PINK? ↗
Active management and a philanthropic mission set Simplify apart, though State Street's lower costs and stronger recent returns appeal to passive investors. 
Via The Motley Fool
Topics ETFs
News headline image
Better Pharma ETF: iShares IHE vs. State Street XPH ↗
IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio. 
Via The Motley Fool
Topics ETFs
News headline image
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma ↗
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly. 
Via The Motley Fool
Topics ETFs
Why Did AQST Stock Plunge 40% In Pre-Market Today? ↗
Via Stocktwits
News headline image
Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals ↗
XPH delivered 19% higher returns over five years despite half the volatility. XBI's 165 holdings offer broader exposure but with a 53% maximum drawdown. 
Via The Motley Fool
Topics ETFs
News headline image
IXJ vs XPH: Global Healthcare ETF or Pharma Focus? ↗
XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading. 
Via The Motley Fool
Topics ETFs
News headline image
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH ↗
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? ↗
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it. 
Via The Motley Fool
Topics ETFs
News headline image
XPH vs PJP: Which Pharma ETF Offers Better Value ↗
State Street's lower costs appeal to buy-and-hold investors, while Invesco's concentrated portfolio and lower volatility suit risk-averse income seekers. 
Via The Motley Fool
Topics ETFs
News headline image
Better Healthcare ETF: State Street's Pharmaceuticals-Focused XPH vs. Invesco's S&P 500-Targeted RSPH ↗
One fund targets pharma exclusively and surged 63% in a year, while the other diversifies across healthcare with lower volatility. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH? ↗
IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH? ↗
IBBQ offers lower costs and broader diversification, while XPH delivered stronger 1-year returns with less volatility. 
Via The Motley Fool
Topics ETFs
News headline image
BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? ↗
Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry. 
Via The Motley Fool
Topics ETFs
News headline image
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio? ↗
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration—key factors shaping their long-term investor appeal. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors. 
Via The Motley Fool
Topics ETFs
News headline image
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗
Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million. 
Via Stocktwits
Topics Intellectual Property
News headline image
Why Did CANF Stock Soar 40% In Pre-Market Today? ↗
The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint. 
Via Stocktwits
News headline image
TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint ↗
The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint. 
Via Stocktwits
Topics Workforce
News headline image
FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development ↗
Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments. 
Via Stocktwits
Topics ETFs Government
News headline image
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results ↗
Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin. 
Via Stocktwits
News headline image
Why Did CRMD Stock Crash 28% Today? ↗
CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data. 
Via Stocktwits
News headline image
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them." 
Via Benzinga
News headline image
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
News headline image
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers. 
Via Benzinga
Topics Government World Trade
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗
Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices. 
Via Benzinga
News headline image
Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy. ↗
The tariffs will impact products imported from Europe, the Trump administration said late Thursday. 
Via Investor's Business Daily
Topics ETFs Government Intellectual Property
News headline image
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗
Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation. 
Via Benzinga
News headline image
Novo Nordisk Shares Plunge Amid Leadership Shakeup (NYSE:NVO)
In a surprising turn of events, shares of pharmaceutical giant Novo Nordisk (NYSE:NVO) fell sharply following the company’s announcement of a significant leadership restructuring. The abrupt changes at... 
Via MarketMinute
Topics ETFs Economy
News headline image
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.